NewAmsterdam Intangible Assets from 2010 to 2026
| NAMS Stock | 34.24 0.65 1.86% |
Intangible Assets | First Reported 2010-12-31 | Previous Quarter 614.1 K | Current Value 334.4 K | Quarterly Volatility 124.8 K |
Check NewAmsterdam Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NewAmsterdam Pharma's main balance sheet or income statement drivers, such as Net Interest Income of 20.4 M, Interest Income of 20.4 M or Depreciation And Amortization of 136.4 K, as well as many indicators such as Price To Sales Ratio of 32.1, Dividend Yield of 0.0 or PTB Ratio of 1.82. NewAmsterdam financial statements analysis is a perfect complement when working with NewAmsterdam Pharma Valuation or Volatility modules.
NewAmsterdam | Intangible Assets | Build AI portfolio with NewAmsterdam Stock |
The evolution of Intangible Assets for NewAmsterdam Pharma provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how NewAmsterdam Pharma compares to historical norms and industry peers.
Latest NewAmsterdam Pharma's Intangible Assets Growth Pattern
Below is the plot of the Intangible Assets of NewAmsterdam Pharma over the last few years. It is non-physical assets possessed by a company, such as patents, trademarks, and copyrights, which provide long-term value. NewAmsterdam Pharma's Intangible Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NewAmsterdam Pharma's overall financial position and show how it may be relating to other accounts over time.
| Intangible Assets | 10 Years Trend |
|
Intangible Assets |
| Timeline |
NewAmsterdam Intangible Assets Regression Statistics
| Arithmetic Mean | 256,265 | |
| Geometric Mean | 238,113 | |
| Coefficient Of Variation | 48.68 | |
| Mean Deviation | 83,965 | |
| Median | 208,000 | |
| Standard Deviation | 124,753 | |
| Sample Variance | 15.6B | |
| Range | 444.1K | |
| R-Value | 0.56 | |
| Mean Square Error | 11.4B | |
| R-Squared | 0.31 | |
| Significance | 0.02 | |
| Slope | 13,774 | |
| Total Sum of Squares | 249B |
NewAmsterdam Intangible Assets History
About NewAmsterdam Pharma Financial Statements
NewAmsterdam Pharma shareholders use historical fundamental indicators, such as Intangible Assets, to determine how well the company is positioned to perform in the future. Although NewAmsterdam Pharma investors may analyze each financial statement separately, they are all interrelated. The changes in NewAmsterdam Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on NewAmsterdam Pharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Intangible Assets | 614.1 K | 334.4 K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.